guidelines for the management of urological cancer - Merseyside ...

For patients referred from the local MDT to the SMDT, the following information is
required:-
• Muscle invasive TCC bladder
• Staging results from the pelvic MR and abdominal/chest CT scan with radiology review
where required
• Histology report with pathology review where required
• Assessment regarding fitness for radical treatment including
• Co-morbidity, Life expectancy
• Bladder symptoms, bladder pathology eg diverticulum, hydronephrosis
• Hip replacements
• Renal function
• Bone biochemistry
Radiology Guidelines
Please refer to the Royal College of Radiologists guidelines attached
http://www.rcr.ac.uk/
Imaging of Cancer Patients
Network approved imaging protocols are detailed in Appendix 9.
6.1 Treatment of new non-muscle invasive tumours – see Figure
2/Appendix 5
At the first resection, as the histology is not available, those patients with clinically
superficial bladder tumours receive intravesical MMC following resection.
pTaG1 or pTaG2 – see Figure 3
• Single dose of intravesical chemotherapy at initial resection(S) [1,2]
• MDT (S)
• Cystoscopy at three months (S)
• At 3 month cystoscopy, assign to a recurrence risk group (S), as follows.
Initial Resection 3 month Cystoscopy Recurrence risk group
Solitary tumour and clear low risk of recurrence
Solitary tumour and recurrence medium risk of recurrence
or
Multifocal tumour and clear medium risk of recurrence
Multifocal tumour and recurrence high risk of recurrence
Page 13 of 44